HomeNewsBusinessEconomyCentre seeks Parliament nod for additional net cash expenditure of up to Rs 1.67 lakh crore

Centre seeks Parliament nod for additional net cash expenditure of up to Rs 1.67 lakh crore

For meeting expenditure towards recapitalisation of public sector banks through government securities, the government has sought Rs 20,000 crore

September 14, 2020 / 14:26 IST
Story continues below Advertisement
Finance Minister Nirmala Sitharaman (File image: Reuters)
Finance Minister Nirmala Sitharaman (File image: Reuters)

In the wake of the coronavirus pandemic-induced recession, the finance ministry has sought Parliament's approval for gross additional expenditure of Rs 2.36 lakh crore, of which the the net cash outgo would be to the tune of Rs 1.67 lakh crore.

The gross additional expenditure, matched by savings of the ministries and departments by enhanced receipts/recoveries, aggregates to Rs 68,868 crore.

Story continues below Advertisement

"The large additional net cash outgo of Rs. 1.67 lakh crore in the first supplementary demand for grants is partly comprised of new items announced under the fiscal support plan, stepped up health expenditure, as well as some items that were under-budgeted earlier, such as the revenue deficit grants in relation to the Fifteenth Finance Commission's recommendations," Aditi Nayar, principal economist, ICRA, said.

Under the Mahatma Gandhi National Rural Employment Guarantee Act (MGNREGA), the government sought Rs 72,000 crore, of which Rs 32,000 crore would be for the creation of capital assets and Rs 40,000 crore would be for transfer of funds to the National Employment Guarantee Fund.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show